文献速递泌尿男性生殖肿瘤

帕唑帕尼与依维莫司交替治疗对比持续帕唑帕尼治疗延缓转移性透明细胞肾细胞癌疾病进展:ROPETAR随机临床试验

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

ROPETAR试验在荷兰17家医院纳入101例初治转移性透明细胞肾细胞癌患者,1:1随机接受帕唑帕尼800 mg/d与依维莫司10 mg/d每8周交替方案(轮换组52例)或持续帕唑帕尼800 mg/d(对照组49例)。轮换组首次进展或死亡中位时间7.4个月(95%CI 5.6-18.4)vs 对照组9.4个月(95%CI 6.6-11.9)(P=0.37),未延长无进展生存、未减少毒性、未改善生活质量。

要点

  • 轮换组首次进展或死亡中位时间7.4个月 vs 对照组9.4个月(P=0.37),无显著差异
  • 轮换组1年PFS1为45%(95%CI 33-60),对照组为32%(95%CI 21-49)
  • 一线治疗期间口腔黏膜炎、厌食、头晕在轮换组更常见,生活质量无差异

核心结论

  • 交替治疗未延长无进展生存、未减少毒性反应、未改善生活质量。
  • 转移性透明细胞肾细胞癌一线治疗中血管内皮生长因子抑制剂仍是最佳方法。

研究设计与样本

  • 开放标签、1:1随机ROPETAR试验(clinicaltrials.gov NCT01408004)。
  • 2012年9月至2014年4月从荷兰17家大区或学术医院纳入101例初治进展性转移性透明细胞肾细胞癌患者,随访至少一年。
  • 轮换组52例接受帕唑帕尼800 mg/d与依维莫司10 mg/d每8周交替方案直至进展;对照组49例接受持续帕唑帕尼800 mg/d直至进展。
  • 进展后轮换组最终轮换至帕唑帕尼或依维莫司单药,对照组开始依维莫司。
  • 主要终点为至首次进展或死亡的生存时间;次要终点包括至第二次进展或死亡时间、毒性反应和生活质量。

主要发现

  • 轮换组中位年龄65岁(范围44-87),对照组中位年龄67岁(范围38-82)。
  • 纪念斯隆凯特琳癌症中心风险分级: favorable 26%、intermediate 58%、poor 15%,两组基线特征与风险分级均衡。
  • 轮换组首次进展或死亡中位时间7.4个月(95%CI 5.6-18.4)vs 对照组9.4个月(95%CI 6.6-11.9)(P=0.37)。
  • 轮换组1年PFS1为45%(95%CI 33-60)vs 对照组32%(95%CI 21-49)。
  • 一线治疗期间口腔黏膜炎、厌食、头晕在轮换组更常见;生活质量未见差异。

临床怎么用

  • 作者结论认为转移性透明细胞肾细胞癌一线治疗中血管内皮生长因子抑制剂仍是最佳方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. OBJECTIVE: To test our hypothesis that an 8-week rotating treatment schedule with pazopanib and everolimus delays disease progression, exhibits more favorable toxic effects, and improves quality of life when compared with continuous treatment with pazopanib. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, randomized (1:1) study (ROPETAR trial). In total, 101 patients with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 2012 and April 2014 from 17 large peripheral or academic hospitals in The Netherlands and followed for at least one year. INTERVENTIONS: First-line treatment consisted of either an 8-week alternating treatment schedule of pazopanib 800 mg/d and everolimus 10 mg/d (rotating arm) or continuous pazopanib 800 mg/d (control arm) until progression. After progression, patients made a final rotation to either pazopanib or everolimus monotherapy (rotating arm) or initiated everolimus (control arm). MAIN OUTCOME AND MEASURES: The primary end point was survival until first progression or death. Secondary end points included time to second progression or death, toxic effects, and quality of life. RESULTS: A total of 52 patients were randomized to the rotating arm (median [range] age, 65 [44-87] years) and 49 patients to the control arm (median [range] age, 67 [38-82] years). Memorial Sloan Kettering Cancer Center risk category was favorable in 26% of patients, intermediate in 58%, and poor in 15%. Baseline characteristics and risk categories were well balanced between arms. One-year PFS1 for rotating treatment was 45% (95% CI, 33-60) and 32% (95% CI, 21-49) for pazopanib (control). Median time until first progression or death for rotating treatment was 7.4 months (95% CI, 5.6-18.4) and 9.4 months (95% CI, 6.6-11.9) for pazopanib (control) (P = .37). Mucositis, anorexia, and dizziness were more prevalent in the rotating arm during first-line treatment. No difference in quality of life was observed. CONCLUSIONS AND RELEVANCE: Rotating treatment did not result in prolonged progression-free-survival, fewer toxic effects, or improved quality of life. First-line treatment with a vascular endothelial growth factor inhibitor remains the optimal approach in metastatic clear cell renal cell carcinoma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01408004.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Cirkel GA, Hamberg P, Sleijfer S, et al. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 27918762. doi:10.1001/jamaoncol.2016.5202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。